Rocket Pharmaceuticals Director Purchase: 10,000 Shares; 30,000 RSUs Vest 6/18/2026

Rhea-AI Filing Summary

Elisabeth Bjork, a director of Rocket Pharmaceuticals, Inc. (RCKT), purchased 10,000 shares of common stock on 08/27/2025 at $3.41 per share, increasing her reported beneficial ownership to 40,000 shares. The filing notes that 30,000 of those shares are restricted stock units that convert one-for-one to common stock and vest in full on June 18, 2026. The Form 4 was signed by an attorney-in-fact for Ms. Bjork.

Positive

• Director purchased 10,000 shares at $3.41, increasing direct reported ownership to 40,000 shares
• 30,000 RSUs vest on June 18, 2026, providing clarity on future share conversion and timing

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director purchased shares and holds RSUs vesting next year, indicating routine insider compensation and ownership alignment.

The transaction is a simple open-market purchase of 10,000 common shares at $3.41, reported on Form 4. Combined with 30,000 RSUs that convert one-for-one and vest June 18, 2026, the directors total reported beneficial ownership is 40,000 shares. This filing reflects standard insider compensation and an increase in direct ownership rather than a derivative exercise or sale. No additional governance actions or changes in board status are disclosed in this filing.

Securities Analyst

TL;DR: Small insider purchase; transaction size appears modest relative to typical market-moving insider activity.

The reported purchase (10,000 shares at $3.41) is a straightforward acquisition recorded under transaction code P. The filing clarifies that a material portion of reported holdings (30,000 RSUs) remains subject to vesting until June 18, 2026, which impacts the timeline for full beneficial ownership. The filing provides precise quantities and prices but no earnings or debt information to affect valuation analysis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bjork Elisabeth

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	08/27/2025		P		10,000	A	$3.41	40,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 30,000 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis and vest in full on June 18, 2026.

	/s/ Martin Wilson, as attorney-in-fact for Elisabeth Bjork	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for RCKT and what is their relationship to the company?

The Form 4 was filed for Elisabeth Bjork, who is reported as a director of Rocket Pharmaceuticals, Inc.

What transaction was reported on the RCKT Form 4 dated 08/27/2025?

The filing reports a purchase of 10,000 shares of common stock at a price of $3.41 per share on 08/27/2025.

How many shares does Elisabeth Bjork beneficially own after the transaction?

Following the reported purchase, Ms. Bjork beneficially owns 40,000 shares in total according to the Form 4.

Are there any restricted stock units (RSUs) disclosed in the filing for RCKT?

Yes, the filing states there are 30,000 RSUs that convert one-for-one to common stock and vest in full on June 18, 2026.

Who signed the Form 4 for Elisabeth Bjork?

The Form 4 is signed by Martin Wilson, as attorney-in-fact for Elisabeth Bjork, dated 08/27/2025.